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OleosinThe potential of oleosins to act as carriers for recombinant foreign proteins in plant cells has been established.
Using the oleosin fusion technology, the protein can be targeted to oil bodies in oilseeds by fusing it to the N-
or C-terminus of oleosin. In this study, aFGF was expressed in Arabidopsis thaliana seeds via oleosin fusion tech-
nology. A plant-preferred aFGF genewas synthesized by optimizing codonusage andwas fused to the C-terminus
of the A. thaliana 18.5 kDa oleosin gene. The fusion gene was driven by the phaseolin promoter to confer seed-
speciﬁc expression of the human acidic ﬁbroblast growth factor in A. thaliana. The T-DNA region of the recombi-
nant plasmid pKO-aFGF was introduced into the genome of Arabidopsis thaliana by the ﬂoral dip method. The
aFGF protein expression was conﬁrmed by SDS-PAGE and western blotting. The biological activity showed that
oil bodies fused to aFGF stimulated NIH/3T3 cell proliferation activity.
© 2015 Published by Elsevier B.V.1. Introduction
Human acid ﬁbroblast growth factor (aFGF), also called FGF-1, the
physiological form of which contains 154 amino acids (Zazo et al.,
1992) is a heparin binding protein. It was involved in a variety of biolog-
ical processes, including angiogenesis, cell proliferation, and differentia-
tion (Kenneth and Guillermo, 1986; Jose Feito et al., 2011). The aFGF
protein is an important member of the growth factor families. The
aFGFwere originally identiﬁed as peptideswithmitogenic activity forﬁ-
broblasts. The aFGF has regenerative capabilities when administered
after focal cerebral ischemia in different species (Mitani et al., 1992;
Sasaki et al., 1992), so it may have broad prospects for the treatment
of acute focal cerebral ischemia (Jose Feito et al., 2011). The aFGF also
has fortissimo tissue-injury repair properties that might be relevant
for medical applications.
Disputes about the safety of using aFGF in the human body have
badly slowed down its therapeutic development. Except for the topicalMTT,3-(4,5-Dimethylthiazol-2-
301 plasmid as a basic skeleton
-speciﬁc promoter, Arabidopsis
nator; pKO-aFGF, The construct
ngineering Research Center of
ultural University, Changchunapplication of aFGF to treat burn wounds in China, no other pharmaco-
logical application of FGF has been approved (Wu et al., 2005). Lozano
et al. (2000) showed that a shortened form of aFGF including amino
acids 28–154 of the full-length sequence plus Met substituted for
Leu27 (aFGF27–154) did not induce cell division but retained the vaso-
active, neuromodulatory, and cardio- and neuro-protective characters
of the full-length aFGF (Xiao ping Wu et al., 2005). In our laboratory, a
shortened form of aFGF including amino acids 20–154 of the full-
length sequence was high-level expressed and puriﬁed in Escherichia
coli and the expression level was up to 150 mg/L. The biological activity
showed that a shortened form of aFGF including amino acids 20–154
has no signiﬁcant differences. Three groups of test results showed that
the degradation problem of N-terminus was solved and dimer forma-
tion is decreased obviously. So we chose a shortened form of aFGF in-
cluding amino acids 20–154. We modiﬁed the N-terminus of the aFGF
gene by eliminating residues 1–19,whichweakened itsmitogenic prop-
erties and preserved its non-mitogenic properties.
The need for cheap production of a mass of proteins has led to a new
industry for producing recombinant proteins in transgenic plants. The po-
tential of molecular pharming, using transgenic plants as bioreactors can
produce therapeutic proteins. Plants as vehicle provide an attractive ex-
pression system for many proteins (Richter et al., 2000; Petolino et al.,
2000; Tacket et al., 1998). The expression of therapeutic proteins
in plant has a safe and low-cost advantage, and process post-
translational modiﬁcations. However, the expression level and stability
of recombinant proteins in plants especially in plant seeds are inﬂuenced
by several factors for example the cis-regulatory elements,mRNA stability
Fig. 2. Agarose gel for screening positive transgenic lines by RT-PCR ampliﬁcation. Lane1
and lane9: positive control (aFGF plasmid); lane2–lane8: the transgenic A. thaliana T3–
1,T3–2,T3–3, T3–4, T3–5, T3–6 and T3–7; lane10–lane12: the transgenic A. thaliana T3–
8,T3–9 and T3–10; lane13: the wild-type A. thaliana; lane14: T3–11.
Fig. 1. Schematicmap of recombinant plasmid pKO-aFGF. The T-DNA region of pCAMBI A-
1301 was replaced by pstI and BstEII between T-Border (LB) and Nos. The 35S-bar gene
was inserted into the T-DNA region by pstI and BstEI. The oleosin gene was fused with
the phaseolin promoter, then fusion gene was inserted into T-DNA region by PstI and
NcoI. The aFGF gene was linked to the 3′-end of oleosin gene in T-DNA region by NcoI
and HindIII. The recombinant plasmid was named pKO-aFGF. The T-DNA of the pKO-
aFGF vector included a phaseolin promoter/terminator, an A. thaliana oleosin gene, aFGF
gene, the 35S promoter, the bar gene and nos gene terminator. PhaP: phaseolin promoter,
Oleasin: A. thaliana oleosin gene, aFGF: acidicﬁbroblast growth factor, PhaT: phaseolin ter-
minator, 35S: CaMV35S promoter, Nos: Nopaline synthase terminator gene.
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2006). Oil bodies (OBs) are lipid-storage organelles in plant seeds that
provide energy for seedlings during germination (Huang, 1996). OBs are
composed of a TAG core surrounded by a phospholipid (PL) monolayer
that contains oleosins, caleosins and steroleosins including several that
stabilize the organelle. OBs can be easily separated from the cell compo-
nents in seeds byﬂotation centrifugation and contain relatively fewdiffer-
ent proteins (Van Rooijen andMoloney, 1995). When used to recover oil
body-associated recombinant proteins, this process greatly enriches for
the target protein and can reduce puriﬁcation steps.
Because of the oil body's peculiar structure, a novel technology
namedoil body fusion technology has been developed inwhich heterol-
ogous proteins are fused to the N- or C-terminus of oleosin in oil body
surface and expressed under the control of an oleosin gene promoter
or seed-speciﬁc promoter (Stoger et al., 2005; Boothe et al., 2010). It is
one of the most popular methods because it can extend protein half-
life, and allows easy transportation and storage (Bhatla et al., 2010).
There have been many reports of oleosin-fusion technology being
usedwith heterologous proteins. Recombinant humanprecursor insulin
fusedwith oleosin has been expressed in Arabidopsis and shown biolog-
ical activity (Nykiforuk, 2006). Human epidermal growth factor (hEGF)
fused with oleosin has also been expressed in Arabidopsis and an accu-
mulation level of 0.12% was achieved (Moloney et al., 2006; Bhatla
et al., 2010). The fusion protein Oleosin-ApoA1 has been expressed in
Arabidopsis and Carthamus tinctorius L. and reached commercial produc-
tion standards (Moloney et al., 2004; Bhatla et al., 2010). Many heterol-
ogous proteins have been expressed in transgenic plants since the
successful production of a mouse monoclonal antibody in plants
(Twyman et al., 2003; Jung et al., 2010). Here, we expressed aFGF in
the oil body of Arabidopsis through the construction of the plant expres-
sion vector pKO-aFGF. The expression of the oleosin-aFGF fusion protein
was checked by SDS-PAGE and the antigenicity was detected by west-
ern blot. The aFGF protein expressed in transgenic A. thaliana seeds
stimulated NIH/3T3 cell proliferation activity.
2. Materials and methods
2.1. Materials
Plasmids and strains: The plasmid pKO for transformation was con-
structed using the pCAMBIA1301 plasmid as a basic skeleton, and
contained the phaseolin promoter/terminator (Patent PCT/US01/
47495), the A. thaliana oleosin gene (AtOLE, GenBank accession no.
X62353.1) 35S promoter (GenBank accession no. AF21 8816.1), bar
gene (GenBank accession AF218816.1) and terminator of nos (GenBank
accession AF234307), aFGF gene (GenBank accession no. BC03 2697.1).
E. coli DH5α and Agrobacterium tumefaciens EHA105 were obtained
from the laboratory of the Engineering Research Center of Bioreactorand Pharmaceutical Development, Ministry of Education, Jilin Agricul-
tural University, China.
Test material: Mature seeds of A. thaliana.
Enzymes and reagents: The restriction enzymes NcoI and HindIII,
pfuDNA polymerase and T4 DNA ligase were purchased from Takara
(Dalian, China). All primerswere synthesized and sequenced by Sangon
Bioengineering Co., Ltd. (Shanghai, China). Kanamycin (Kan), strepto-
mycin (Str) and rifampicin (Rif) were purchased from Sigma (Hong
Kong, China). Glufosinate was purchased from the Boehringer Mann-
heim Corporation (Mannheim, Germany). Rabbit anti-aFGF polyclonal
antibody was purchased from Abcam, Inc. (Cambridge, MA, USA).
Isopropyl-β-D-thiogalactoside (IPTG) and methylthiazol tetrazolium
(MTT) were obtained from Gold Biotechnology (St. Louis, MO, USA).
Dulbecco's modiﬁed Eagle medium (DMEM) was purchased from
Invitrogen (Carlsbad, CA, USA).
2.2. Construction of the pKO-aFGF vector
The recombinant plasmid skeleton was derived from pCAMBIA1301
plasmid vector. The T-DNA region of pCAMBIA1301was replaced by pstI
and BstEII between T-Border (LB) andNos. The 35S-bar genewas ampli-
ﬁed by PCR from pEGAD plasmid using the forward primer with PstI,
NcoI, HindIII, kpnI (CCCTGCA GCCATGGTCTAGAGGTACCATCCGTCAACAT
GGTGG) and the reverse primer with BstEII (GGGTTACCTCAGATCTCG
GTGACGGGC). The 35S-bar gene was inserted into pCAMBIA1301-
29KD
66.4KD
97.2KD
M     1 2 3 4 5 6 7
44.3KD
Fig. 3. Identiﬁcation of SDS-PAGE of crude oil bodies in transgenic Arabidopsis thaliana. M: Proteinmarker; lane1–lane6: the crude oil body from T3 transgenic A. thaliana T3–3, T3–4, T3–6,
T3–7, T3–10 and T3–11; lane7: the crude oil body from wild-type (WT) A. thaliana.
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phaseolin promoter was ampliﬁed by PCR from Phaseolus vulgaris ge-
nome (the forward primer: CGCTGCAGGAATTCATTGTACTCCCAG, the re-
verse primer: CCTCTAGCTGTATCCGCCATAGTAGAGTAGTATTGAATAT
GAG). The RNA from Arabidopsis thaliana seeds was extracted and re-
versed transcription into cDNA. The A. thaliana oleosin gene was ampli-
ﬁed by PCR from A. thaliana cDNA (the forward primer: CTCATATTCAAT
ACTACTCTACTATGGCGGATACAGCTAGA GGAAC, the reverse primer:25KD 
35KD 
55KD 
M T3-3 T3-4 T3-6
Fig. 4.Detection on aFGF protein of the transgenic Arabidopsis thaliana by western blot and the
T3–4, T3–6, T3–7, T3–10, and T3–11; lane7: the crude oil body from wild-type (WT) A. thalianCATGCCATGGTAGTAGTGTGCTGGCCACCACG). The A. thaliana oleosin
gene was fused with the phaseolin promoter by fusion PCR method (the
forward primer: CGCTGCAGGAATTCATTGTACTCCCAG,the reverse primer:
CATGCCATGGTAGTAGTGTGCTGGCCACCACG). The fusion gene was
inserted into pCAMBIA1301-35S-bar vector by pstI and NcoI, named
pCAMBIA 1301-F-B. The phaseolin terminator was ampliﬁed by PCR
from Phaseolus vulgaris genome. It was inserted into pCAMBIA1301-F-B
vector by HindIII and kpnI, named pKO vector (Fig. 1).T3-7 T3-10 T3-11 WT 
gray value analysis of lane1–lane6: the crude oil body from T3 transgenic A. thaliana T3–3,
a.
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the pUC57-aFGF vector with unique NcoI and HindIII sites was synthe-
sized by Sangon Biotech. The pKO plasmid was extracted from E. coli
and double restriction enzyme digested with NcoI and HindIII. The
aFGF gene was inserted into the pKO plasmid. The new recombinant
plasmid namedpKO-aFGFwas transformed into E. coliDH5α competent
cells. The pKO-aFGF recombinant plasmid was extracted from E. coli
DH5α and tested by PCR and digestion. Then, it was transformed into
Agrobacterium EHA105 competent cells using the freeze–thaw method
(Höfgen and Willmitzer, 1988). Positive colonies were identiﬁed by
PCR with aFGF-speciﬁc primers: F1 (5 -ATGGCTAACTACAAGAAG-3 ;
forward) and R1 (5 -TTAATCAGAAGAA ACTGGCAA T-3 ; reverse).
ExTaq DNA polymerase (Takara Bio, Dalian, China) was used in the
PCR reaction system. A total of 30 cycles were performed with a dena-
turation step at 94 °C for 30 s, an annealing step at 60 °C for 45 s and
an elongation step at 72 °C for 90 s.
2.3. Transformation into A. thaliana
A. thaliana Columbia ecotype (4–5 weeks old, containing numerous
unopened ﬂoral buds) was chosen as the transformation host. Prepara-
tion of liquid medium containing A. tumefaciens, 5% sucrose, 0.1% B5,
0.001% 6-BA, 0.009% 1 M sodium hydroxide and 400 μL/L of the surfac-
tant Silwet L-77wasperformed according to theArabidopsis testmanual
(Weigel and Glazebook, 2004). Unopened A. thaliana ﬂoral buds were
inﬁltrated for 7 min, and the plants were laid ﬂat under a plastic dome
and cultured in the dark for 24–48h after inoculation. Then, the infected
A. thaliana plants were transferred to normal lighting conditions and
grown until seeds were collected (T1).
2.4. Selection of transgenic A. thaliana
The T1 transgenic seeds were stratiﬁcated at 4 °C for 2 days, Primary
transformant (T1) seeds were screened on 1/2 Murashige and Skoog
(MS) basal plates supplementedwith 11mg/mLBasta. The independentFig. 5. The activities assay of aFGF protein in the transgenicArabidopsis thaliana seeds. Dose–resp
the percentage increases in absorbance (570/630 nm). The test sample included the standard b
aFGF7 ( ), aFGF10 ( ), aFGF11 ( ).Basta-resistant lines were transferred to soil after screening on culture
medium and were further screened in the soil [vermiculite: soil (V:V)
7:3] with 1% Basta. A. thaliana plants were further grown until collected
T2 seeds. The T2 seeds were screened by Basta and then collected T3
seeds. The seeds from independent homozygous T3 lines were used
for protein expression analysis and activity assay.
2.5. Oil body puriﬁcation
Oil bodies were puriﬁed using the method described by Tzen et al.
(1997). Twenty milligrams of seeds were ground in 200 μL sodium
phosphate buffer (pH 7.5). The suspension was spun at 10,000 × g
and 4 °C for 30 min. The ﬂoating oil body fraction was collected, resus-
pended in 200 μL sodiumphosphate buffer (pH 7.5), and spun as before.
After centrifugation and removal of the upper buffer, the oil body frac-
tion was collected and stored at 4 °C until further use.
2.6. Analysis of aFGF protein linked to oil body
Twenty milligrams of seeds were ground in 200 μL sodium phos-
phate buffer (pH 7.5). The loading quantity of sample was 10 μL crude
oil body and it was separated by 12% acrylamide in SDS-PAGE. The pro-
teins were transferred onto Immobilon-P polyvinylidene diﬂuoride
(PVDF) membranes (PerkinElmer, Boston, MA, USA) using a SEMI-
DRY Transfer Cell (Bio-Rad Laboratories, Hercules, CA, USA), and
immunoblotted with a Rabbit anti-aFGF polyclonal antibody (Abcam)
according to the manufacturer's protocol. Immunoreactive bands were
checked with western blotting luminal reagents.
2.7. Activity assay of aFGF
To verify that the aFGF produced and puriﬁed from A. thaliana had a
stimulatory effect on the proliferation of NIH/3T3 cells, an MTT assay
was performed. NIH/3T3 cells were seeded in ﬂat-bottomed, 96-well
plates at an initial density of 5 × 104 cells per mL (100 μL per well)onse curves for proliferation activity. Increase of NIH/3T3ﬁbroblast cellswere expressed as
FGF protein ( ), oil body fromwild-type A. thaliana ( ), aFGF3 ( ), aFGF4 ( ), aFGF6 ( ),
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of incubationwith aFGF, 20 μLMTT solutionwas added to eachwell. The
cells were then incubated for a further 4 h at 37 °C, the culture medium
included the MTT solution in the wells was removed, and 150 μL DMSO
was added to each well and mixed thoroughly to dissolve the crystals.
The plates were read at 570/630 nm in a Microplate Reader model
450 to obtain absorbance values.
3. Results and discussion
3.1. Construction of a plant oil body expression vector
The T-DNA region of the pKO plasmid contained a phaseolin pro-
moter, oleosin gene, phaseolin terminator, 35S promoter, bar gene
andnos gene. The phaseolin promoter controls tissue-speciﬁc transgene
expression during seed development. For the pKO-aFGF plasmid, we
constructed an aFGF gene expression cassette (Fig. 1) containing the
aFGF gene under the control of the phaseolin seed-speciﬁc promoter
(phaP)/terminator (phaT). This construct enabled speciﬁc expression
in A. thaliana seeds. The oleosin gene was as signal peptide to carry
aFGF anchoring in oil body surface.
3.2. RT-PCR detection of recombinant aFGF transcripts in transgenic
Arabidopsis
The pKO-aFGF plasmid was transformed into A. thaliana by a ﬂoral
dip method. Primary transformant seeds were screened on 1/2 MS
basal plates supplemented with 11 mg/mL Basta. The independent
Basta-resistant lines were transferred into soil to continue to screen
and were further conﬁrmed using the aFGF cDNA as a template. The
aFGF transcriptswere detected by RT-PCR. Of the eleven analyzed trans-
genic plants, six exhibited clear bands. A speciﬁc 423 bp PCR product
was generated. The six lines showed the target bands among twelve in-
dependent Basta-resistant lines and the positions of the target bands
were expected at 423 bp (Fig. 2). Therefore, the aFGF proteins were
expressed at the transcriptional level.
3.3. Expression of recombinant aFGF protein in transgenic A. thaliana
To evaluate the accumulation of the oleosin-aFGF fusion protein in
pKO-aFGF transformants, the crude oil body was extracted and oil
body-associated proteins of transgenic (T3–3, T3–4, T3–6, T3–7, T3–
10, T3–11) and wild-type A. thaliana plants were analyzed by SDS-
PAGE and western blotting. The aFGF gene was predicted to encode
135 amino acids. Determination of the crude oil body extracts from
the pKO-aFGF-transformed plants showed an immunoreactive protein
with a molecular weight of 33.5 kD, which is identical size to oleosin-
aFGF fusion protein, suggesting that the oleosin precursor was properly
assembled in the transgenic A. thaliana oil body. The six pKO-aFGF-
transformed lines also exhibited positive signals in seeds.
However, the accumulation of oleosin-aFGF fusion protein in the oil
body of transgenic lines was not accurately quantiﬁed, because ELISA
method was not suited for testing fusion protein in the oil body. So
the fusion protein was roughly quantiﬁed by western blot method.
There was no band at this position in the wild-type seeds (Figs. 3 and
4). Then there were more oil body-associates observed in transgenic
lines #7, 10, and 11 and WT than the others. Furthermore, these differ-
ences may have come from the puriﬁcation efﬁciency during oil body
preparation.
3.4. NIH/3T3 activity analysis of plant oil bodies containing the aFGF protein
TheNIH/3T3 cell line is generally used for evaluation of the biological
activity of aFGF. To evaluate the biological activity of different transgenic
lines (T3–3, T3–4, T3–6, T3–7, T3–10, T3–11), NIH/3T3 cells were used
to test the stimulation of cell proliferation. As shown in Fig. 5, thestandard bFGF concentration was set as a gradient from 0.04883 to
12.5 IU/mL. The results suggested that aFGF proteins from the T3 differ-
ent transgenic lines had a dose-dependent cell proliferative effect on the
NIH/3T3 cells. The oil bodieswith aFGF from different lines had stimula-
tion of cell proliferation activity that was higher than the bFGF standard
protein.
Oil body-based pharmaceutical formulations include therapeutic, di-
agnostic and delivery agents. Oil body-based emulsions can be used as
adjuvants in pharmaceutical protein base for dermatological products,
components for orally administered medicines, etc. In these products
oil bodies may also carry an active ingredient to be delivered to host,
if needed. Personal care products wherein oil body-based emulsions
may be used include various cosmetic and cosmeceutical products
such as creams, lotions and makeup products, hair care products, and
bath products such as soaps, washes and cleansers (Deckers et al.,
2001, 2003). In products like toothpaste, oil bodies may also serve as
carriers of components such as ﬂavoring agent, ﬂuoride, silicas, chelat-
ing agents, and sweetener. The recombinant proteins expressed in the
oil body can be stored for longer periods than those obtained from
other sources. GUS enzyme has been reported to remain active for
more than one year when expressed as oleosin fusion in seeds (Van
Rooijen and Moloney, 1995). Moreover, recombinant seeds can be eas-
ily transported. Furthermore, proper refolding of proteins takes place
spontaneously when expressed on oil bodies (Nykiforuk et al., 2005).
Recombinant proteins can be expressed in the oilseeds themselves, or
otherwise the protein can be expressed in any system of choice. It can
then be targeted to oil bodies for puriﬁcation and refolding. So the oil
body expression system was the better option than the other different
expression systems. The aFGF fused to the C-terminus of oleosin and
expressed under the control of a seed-speciﬁc promoter. Thus, expen-
sive steps needed for puriﬁcation and refolding of proteins are not re-
quired. The expression of aFGF with plant organelle signaling
sequences need to purify aFGF protein, thus the puriﬁcation cost of
products should be increased. The oil body linked to aFGF was applied
in many ﬁelds. Many researches were done in SemBioSys Genetics Inc.
The oil body was suitable for expressing FGF protein.
4. Conclusions
Here, an aFGF gene was expressed by A. thaliana and accumulated in
the transgenic seeds. We successfully constructed the plant binary ex-
pression vector pKO-aFGF and T3 transgenic homozygotes were obtain-
ed. The oil body-associated proteins were analyzed by SDS-PAGE and
western blotting, and the results showed that the T3–3 and T3–4 trans-
genic plants expressed the recombinant protein at relatively low levels,
while the T3–10 line expressed it at relatively high levels. The results of
NIH/3T3 cell analysis demonstrated that the activity of aFGF from the
transgenic A. thaliana seeds was higher than that of bFGF standard pro-
tein. This is the ﬁrst trial of aFGF production in an oil body expression
system, and the recombinant protein exhibited typical activity. This re-
sult might be useful for the mass production of aFGF. We have con-
ﬁrmed that the oil body expression system can be used effectively for
the production of aFGF.
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